Article
PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2014
Markou Athina, Farkona Sofia, Schiza Christina, Efstathiou Tonia, Kounelis Sophia, Malamos Nikos, Georgoulias Vassilis, Lianidou Evi
Abstract excerpt
PURPOSE: Molecular characterization of circulating tumor cells (CTC) is crucial for the investigation of molecular-targeted therapies while PIK3CA somatic mutations play a crucial role in therapy response. We investigated the presence of PIK3CA mutations in CTC and whether this is associated with clinical outcome. EXPERIMENTAL DESIGN: We developed and validated an ultrasensitive methodology for the detection of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
